Cancer Monoclonal Antibodies Market
According to Intent Market Research, the Cancer Monoclonal Antibodies Market is expected to grow from USD 73.1 billion in 2023 at a CAGR of 10.4% to touch USD 146.5 billion by 2030. The Cancer Monoclonal Antibodies Market is dominated by key players such as Roche Holding AG, Bristol-Myers Squibb, Merck & Co., Inc., AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Eli Lilly and Company, Pfizer Inc., GSK Plc, Sanofi S.A., Regeneron Pharmaceuticals, Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Bayer AG.